Fed. Circ. Won't Revisit Battle Over Sensipar Generics
The Federal Circuit on Wednesday rejected bids by Amgen and Amneal to reconsider its mixed decision about which proposed generic drugs infringe Amgen's patented medication Sensipar, which is given to kidney...To view the full article, register now.
Already a subscriber? Click here to view full article